Deferiprone (Ferriprox)


 CADTH recommends that Ferriprox should be reimbursed by public drug plans for the treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias if certain conditions are met.
 covered based on criteria used each programs deferasirox (DFX), orally administered SCD and anemias.
 only prescribed clinicians who have expertise managing cost is not more than lowest chelation therapy treat